Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04198818 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors
A Phase 1 study, sponsored by Haihe Biopharma Co..
- Terminated
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
NCT04198818 is a Phase 1 study that was terminated before completion, run by Haihe Biopharma Co.. The registered enrollment target is 37 participants.
The verdict
NCT04198818, a Phase 1 study, was terminated before completion, sponsored by Haihe Biopharma Co..
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
Study Summary
This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a Phase II dose extension stage.
Interventions
- DRUG HH2710
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2020-01-07 |
| Est. Completion | 2023-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04198818
The ClinicalTrials.gov registry entry for NCT04198818 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 37 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Haihe Biopharma Co., which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which HH2710 is the first listed.
NCT04198818 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04198818 about?
NCT04198818 is a clinical study titled "A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors". This is a First-in-Human, Open Label, Phase I/II Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patients with Advanced Tumors, composed of a Phase I dose escalation and dose expansion stage and a Phase II dose extension stage.
What is the current status of trial NCT04198818?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2020-01-07. Estimated completion is 2023-03-31.
What interventions are being tested in trial NCT04198818?
The interventions under investigation include: HH2710 (DRUG).
Who is sponsoring clinical trial NCT04198818?
This trial is sponsored by Haihe Biopharma Co., which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.